Biotech
DUBLIN, IRELAND: Acquisition Bolsters Primary Care Product Portfolio; Horizon to Host Conference Call/Webcast at 8:00 a.m. EST
...
SAN DIEGO, CA: Dr. Patel to Apply His Experience in Over 17 FDA Trials to Accelerate Development of HemaXellerate and dCellVax
...
LONDON, ONTARIO: P53-Dependent Cancer Treatment IP Coverage Extended to Home Market
...
LAVAL, QUEBEC: - Follows positive review of PBI-4050 data by external IPF panel of experts - IPF clinical program to commence in Q4 2014
...
KING OF PRUSSIA, PA: Phase 2 Clinical Study in Friedreich's Ataxia Patients Shows Strong Efficacy Signal; Management Estimates Peak Net Sales Potential for ACTIMMUNE of $500 Million With FA Approval
...
VANCOUVER, BRITISH COLUMBIA: Added Resources Build on Expertise and Reduce Drug Development Life Cycle as Company Continues Significant Development of Its Kinase Programs
...
SAN DIEGO, CA: Cell Therapy and Gene Silencing Combined for New Treatment of Advanced Breast Cancer Anticipated Clinical Trials to Validate dCellVax Platform, Allow for Expansion Into Other Cancers dCellVax Can Be I ...
MANCHESTER, NH: Increases Number of Medical Advisory Board Members to Eight
...
MANCHESTER, NH: Application Inspired by Recently Discovered Mechanism of Action of BTI-320
...
LONDON, ONTARIO: Significant Impact of COTI-2's p53-dependent Mechanism of Action on Cancer to Be Highlighted
...
